Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

  • STATUS
    Recruiting
  • days left to enroll
    60
  • participants needed
    218
  • sponsor
    Cidara Therapeutics Inc.
Updated on 13 June 2021
antibiotic therapy
antibiotics
fluconazole
caspofungin
antifungal agents
antifungal therapy
blood culture
candidiasis
candidemia
microscopic examination

Summary

The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).

Description

A Phase 3, multicenter, prospective, randomized, double-blind, efficacy and safety study of Rezafungin for Injection versus an active comparator regimen of caspofungin followed by optional oral fluconazole step-down therapy in subjects with candidemia and/or invasive candidiasis.

Details
Condition Candidiasis, Invasive Candidiasis, Mycoses, Candidemia, Systemic Fungal Infections, Candidemia/Candidiasis, Systemic Candidiasis, Fungal Infections, fungal infection, mycosis, fungal disease
Treatment Oral placebo, Caspofungin, fluconazole, intravenous placebo, Rezafungin for Injection
Clinical Study IdentifierNCT03667690
SponsorCidara Therapeutics Inc.
Last Modified on13 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Willing and able to provide written informed consent. If the subject is unable to consent for himself/herself, a legally acceptable representative must provide informed consent on his/her behalf
Males or females 18 years of age
Established mycological diagnosis of candidemia and/or invasive candidiasis from a sample taken 4 days (96 hours) before randomization defined as
blood culture positive for yeast or Candida OR
Positive test for Candida from a Sponsor-approved rapid IVD OR
Positive gram stain (or other method of direct microscopy) for yeast or positive culture for Candida spp. from a specimen obtained from a normally sterile site
Presence of one or more systemic signs attributable to candidemia or invasive candidiasis appearing from 12 hours prior to the qualifying positive culture through time of randomization
Willing to initiate or continue medical treatment to cure infections, including receipt of antibiotics and surgical procedures, if required
Female subjects of childbearing potential (all female subjects between 18 years <2 years post-menopausal unless surgically sterile) must agree to and comply with using one barrier method (e.g., female condom with spermicide) plus one other highly effective method of birth control, or sexual abstinence while participating in this study. Male subjects must be vasectomized, abstain from sexual intercourse, or agree to use barrier contraception, and also agree not to donate sperm while participating in the study and for 90 days thereafter (and at least 120 days from the last dose of study drug)
For Candidemia only subjects, drawing of a set of blood cultures within 12 hours prior to randomization in the study. The result of these blood cultures is not required for inclusion in the study

Exclusion Criteria

Any of the following forms of invasive candidiasis at baseline
Septic arthritis in a prosthetic joint (septic arthritis in a native joint is allowed)
Osteomyelitis
Endocarditis or myocarditis
Meningitis, endophthalmitis, chorioretinitis, or any central nervous system infection
Chronic disseminated candidiasis
Urinary tract candidiasis due to ascending Candida infection secondary to obstruction or surgical instrumentation of the urinary tract
Received systemic treatment with an antifungal agent at approved doses for treatment of candidemia for >48 hours (e.g., >2 doses of a once daily antifungal agent or >4 doses of a twice daily antifungal agent) 4 days (96 hours) before randomization
Exception: Receipt of antifungal therapy to which any Candida spp. isolated in culture is not susceptible
Alanine aminotransferase or aspartate aminotransferase levels >10-fold the upper limit of normal
Severe hepatic impairment in subjects with a history of chronic cirrhosis (Child-Pugh score >9)
Presence of an indwelling vascular catheter or device that cannot be removed or an abscess that cannot be drained and is likely to be the source of candidemia or invasive candidiasis
Known hypersensitivity to Rezafungin for Injection, caspofungin, any echinocandin, or to any of their excipients
Meets National Cancer Institute Common Terminology Criteria for Adverse Events, version 5, criteria for ataxia, tremor, motor neuropathy, or sensory neuropathy of Grade 2 or higher
History of severe ataxia, tremor, or neuropathy or a diagnosis of multiple sclerosis or a movement disorder (including Parkinson's Disease or Huntington's Disease)
Planned or ongoing therapy at Screening with a known neurotoxic medication
Previous participation in this or any previous rezafungin study
Current participation in another interventional treatment trial with an investigational agent
Recent use of an investigational medicinal product within 28 days of the first dose of study drug or presence of an investigational device at the time of screening
Pregnant or lactating females
The Principal Investigator (PI) is of the opinion the subject should not participate in the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note